Background-Recent studies have suggested that, in patients with chronic hepatitis C, elevated iron stores are predictive of a poor response to interferon. Ains-To assess liver iron concentration and distribution before and after interferon treatment in patients with hepatitis C in order to evaluate further the role of iron in the pathogenesis of hepatitis C. Patients-Fifty five patients with hepatitis C treated with alpha interferon for six months. Methods-Patients were evaluated for liver iron concentration (normal value <36
Background-Recent studies have suggested that, in patients with chronic hepatitis C, elevated iron stores are predictive of a poor response to interferon. Ains-To assess liver iron concentration and distribution before and after interferon treatment in patients with hepatitis C in order to evaluate further the role of iron in the pathogenesis of hepatitis C. Patients-Fifty five patients with hepatitis C treated with alpha interferon for six months. Methods-Patients were evaluated for liver iron concentration (normal value <36 tumoUg), and liver iron distribution before and six months after therapy. Results-At entry: liver iron concentration was elevated in 16/55 patients (29%); iron stainimg (Perls' staining) was found in 31/55 patients (56%) mainly within Kupffer and endothelial cells. Iron load was significantly higher in patients with the most histological inflammatory activity. Following treatment: liver iron concentration decreased significantly (40 (24) to 30 (17) ,umoVg, p=0.001); this was related to iron depletion in mesenchymal cells. Iron depletion occurred regardless of the response to therapy. Elevated liver iron concentration was not found to be a predictive factor of failure of interferon.
Conclusion-Although liver iron stores were usually normal or only slightly elevated in patients with chronic hepatitis C, biochemical and histological liver iron content decreased following treatment due to the diminution in mesenchymal iron deposits. Iron depletion was interpreted as both a consequence of the antiinflammatory effect of treatment and a factor of improvement in liver histology. (Gut 1997; 41: 115-120) Keywords : chronic active C hepatitis; interferon; iron overload; response to interferon treatment Recent studies have suggested that, in patients with chronic hepatitis C, elevated iron stores assessed by either serum ferritin"13 and/or liver iron concentration" are predictive of a poor response to interferon (IFN) treatment. Despite hepatic iron concentrations which are often within the normal range,46 studies of iron depletion by venesection have been performed to try to improve the response rate to interferon treatment.7~The increase in liver iron could be related to the activity of the inflammatory process as suggested by the correlation between: serum ferritin and the degree of hepatic injury (measured by the serum transaminases activity)6; and the presence of iron deposits within Kupffer cells and portal macrophages.10 If hepatic iron deposition is a secondary response to chronic inflammation, IFN treatment should result in a decrease in hepatic iron. In this study, the effect of antiviral treatment on liver iron concentration and distribution was studied before and after treatment to evaluate further the role of iron in the pathogenesis of chronic hepatitis C.
Methods

SELECTION OF PATIENTS
Fifty five patients (36 males and 19 females) with chronic hepatitis C were studied retrospectively. All had been enrolled into a randomised trial comparing IFN for six months (5 million units for the first month (ml), 3 million units for the second month (m2), and 3 or 5 million units for the last four months according to whether serum alanine aminotransferase (ALT) levels had been normalised or not) (n=28) versus INF from ml to m6 plus ursodeoxycholic acid (UDCA, 10 mg/kg/day) from ml to m9 (n=27)."
Patients were selected on the basis of the availability of a liver biopsy specimen both before (mO) and after (ml2) treatment; this was not the case for the 25 remaining patients included in the therapeutic trial. As the IFN and IFN+UDCA treated groups were identical with respect to: clinical, biochemical, and virological data; response to therapy; and iron studies ( (21) 4 (14) 7 (25) 7 (25) 13 (23) 11 ( 
No significant difference was found between the two treatment groups for all data. IFN, interferon; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; LIC, liver iron concentration.
5' non-coding region (sense pri (5'GTCTAGCCATGGCGTTAG1I antisense primer RC2 (5'TCTCGC CACGCCCAA3')), which corresp spectively to nucleotides 246 to 265 115 on the HCV1 sequence.12 Q HCV-RNA and genotype were not; this study. Response to treatment w; according to HCV-RNA: "respc defined as negative viraemia at the e treatment; "non-response" as positiv at the end of IFN treatment; "res relapse" as negative viraemia at thee treatment and positive viraemia months of follow up; and "sustained as negative viraemia after six month up. (17) ,umol/g, p=0 001).
Evolution of histological iron A significant decrease in total iron score (2-9 (3.7) to 1-3 (2) pLmolIg, p=0 001) was also found following treatment. Iron distribution was modified in the following way: there was a significantly lower mesenchymal iron score in the second liver biopsy series (1L8 (2 8) to 0 9 (1.6) ,umol/g, p=001), while the hepatocytic iron score remained unmodified (figs iB, 2); the decrease in total iron score was therefore mainly related to the removal of iron from mesenchymal cells.
Evolution of iron status according to histological activity (META VIR score) The total and mesenchymal iron scores were significantly higher in patients with the most active disease, and a decrease in total and mesenchymal iron scores was found following treatment, irrespective of the initial degree of disease activity (fig 3) . The hepatocytic iron score did not differ according to disease activity (data not shown).
RESPONSE TO TREATMENT ACCORDING TO IRON STATUS
At the end of IFN therapy (m6), patients were distributed into responders (n=33, 60%) and non-responders (n=22, 40% 
